Covaxin, India's first COVID-19 vaccine candidates today has started its human trial at All India Institutes of Medical Sciences (AIIMS), Delhi.
Over 2,000 volunteers have enrolled for the first phase of human clinical trial of Covaxin. India's COVID-19 vaccine has started the human trial on July 15.
The vaccine has been developed by the Hyderabad-based pharmaceutical company Bharat Biotech in collaboration with National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR).
AIIMS-Delhi is is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II trial.